Abstract
One of the key pathogenic mechanisms of the arterial hypertension (AH) development in patients with metabolic syndrome is the activation of the renin-angiotensin-aldosterone system (RAAS). According to these advantages we need to use drugs inhibiting the RAAS in the treatment of AH patients. This article demonstrates the information about the new Angiotensin II receptor blocker (azilsartan) application in AH patients with metabolic disorders. There are several studies showing the high antihypertensive efficiency of azilsartan as compared with other antihypertensive drug classes in patients with obesity and metabolic disorders. According to the pilot studies, azilsartan has additional positive metabolic effects: increases tissue sensitivity to insulin and reduces body fat mass.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
